Andere talen VYNE Therapeutics Inc.

Aandelen

VYNE

US92941V3087

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 28-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,97 ^USD	0,00%		+8,24%	-15,45%

24/06	Arvinas, Inc. Benoemt Andrew Saik tot penningmeester	CI
13/06	Vyne Therapeutics kondigt de dosering aan van de eerste deelnemers aan de Fase 1A-studie van de nieuwe Bd2-selectieve Bet-remmer Vyn202	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum	26/06
Arvinas, Inc. Appoints Andrew Saik as Chief Financial Officer	24/06
Arvinas, Inc. Appoints Andrew Saik as Treasurer	24/06
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202	13/06
Vyne Therapeutics Announces Dosing of First Participants in Phase 1A Trial of Novel Bd2-Selective Bet Inhibitor Vyn202	13/06
Top Premarket Gainers	07/06
VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201	05/06
VYNE Therapeutics Inc. Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201	05/06
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $98,000	09/05
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update	09/05
VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
VYNE Therapeutics Says US FDA Clears its Investigational New Drug Application for Potential Autoimmune Treatment	06/05
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor	06/05
Vyne Therapeutics Announces FDA Clearance of IND Application for Vyn202, A Novel Bd2-Selective Bet Inhibitor	06/05
VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting	01/05
VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	19/03
VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
VYNE Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q4 Revenue $76,000	29/02
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update	29/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen VYNE Therapeutics Inc.

Aandelen

VYNE

US92941V3087

Andere talen

Filters